Navigation Links
Innocoll Announces Appointment of Anthony H. Wild Ph.D. to Chairman of the Board

ASHBURN, Va., June 17 /PRNewswire/ -- Innocoll Inc. today announced that its board of directors appointed Anthony H. Wild, Ph.D. to the post of chairman of the board, effective immediately.  Dr. Wild succeeds Rolf Schmidt who will remain on the board after serving as chairman since the company's inception.

Dr. Wild has served as a director of the company since July 2008.  He is a co-founder and General Partner of BOWS Pharmaceuticals AG, a Swiss drug-delivery technology company, and a member of the boards of directors of several privately-owned specialty pharmaceutical and biotechnology companies. He also chairs the board of advisors of Ferrer, Freeman and Co., a healthcare private equity firm.  He is on the board of advisors of Celtic Therapeutics, a pharmaceutical venture fund and is an advisor to Golden Pond Healthcare Inc., a special acquisitions corporation.

Dr Wild was the Chairman of MedPointe Pharmaceuticals Inc., a privately-held specialty pharmaceutical company based in Somerset (NJ), until its acquisition by Meda AB of Sweden in 2007.  He also served as CEO from 2001 until 2006.  

Between 1995 and 2000, Dr Wild worked for the Warner-Lambert Company, of Morris Plains (NJ). Starting as President of Warner-Lambert's Parke-Davis (North America) unit, he was promoted to Executive Vice President and President of its global Pharmaceutical Sector in 1996.  Before joining Warner-Lambert, Dr Wild spent 22 years with the Schering-Plough Corporation in various roles culminating as President of its Japanese operations.

Dr Wild graduated in 1968 from the University of York where he earned an honors degree in Chemistry.  He also holds a Ph.D. degree in physical chemistry from the University of Cambridge (Churchill College).

Dr. Wild commented, "I am honored to take over from Rolf Schmidt as Chairman and would like to thank him for his vision in founding Innocoll and leading the Board up to this point.  I am very pleased how far the company has come and am excited at our prospects in the coming months and years".

Rolf Schmidt noted, "I have known Dr. Wild for a number of years as a professional with just the skill set to help bring the growing pipeline of the company's products to market. His deep understanding of the industry is a special asset of significant value to the growth of our company. It is a privilege to work with Tony in this exciting period."

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx® and Liquicoll®. Innocoll has licensed its US marketing rights to its lead product, CollaRx GENTAMICIN SURGICAL IMPLANT to Baxter Healthcare, a division of Baxter International Inc. (NYSE: BAX.) The product is currently in phase 3 development in the US for the prevention of surgical site infections.  It is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine Implant for the management of post-operative pain, both of which are currently in Phase 2 development. For more information, please visit

SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
2. Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge
3. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
4. Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors
5. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
6. Innocoll Announces Closing of $30 Million Equity Financing Investment
7. Healthcare Data Solutions Announces New Service, PrescriberPRO Rx
8. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
9. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
10. FASEB Announces Recipient of the 2011 Excellence in Science Award
11. AgFeed Industries, Inc. Announces Stocking Agreement for Xinyu Production Pod
Post Your Comments:
(Date:10/13/2015)... -- PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $.1035, ... average with 1,308,352 shares being traded. PMCB shares have been ... low of $.072 in September, then bouncing back to current ... due diligence will show investors in PharmaCyte Biotech, Inc. information ... using the link below at no cost. ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... and assessment of organotypic 3D cell culture models, has launched a 14 ... in their patent-pending 3D InSightâ„¢ Human Liver Microtissues. The service streamlines toxicity ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... President. Steve joins as the Pistoia Alliance continues to drive to increase the ... non-profit Pistoia Alliance is focusing its vision and expanding its work in supporting ...
(Date:10/13/2015)... Oct. 13 2015 Research and Markets( ... & Europe Markets for Bone Morphogenetic Protein Growth Factor ... offering. --> --> ... the formation of bone after a fracture. In nature, ... in the formation of the skeleton. There are twenty ...
Breaking Biology Technology:
(Date:10/13/2015)... Feedzai , a data science company ... and minimize risk in the financial industry, announced a ... fraud prevention solution that gives merchants the ability to ... email address. The two companies will provide their mutual ... risk assessment with fraud risk scoring to streamline transaction ...
(Date:10/13/2015)... Dragon Capital Group Corp. (OTC: DRGV), a holding company ... announced today that its wholly owned subsidiary, Shanghai Yazheng Information ... Naked Eye 3D System for a period of one year. ... is expected to be completed in 2015. Management estimates the ... --> --> This Multi-Format Naked ...
(Date:10/13/2015)... DUBLIN , Oct. 7, 2015 Research ... of the "India Biometrics Authentication & Identification Market ... offering. --> --> ... from $823.46 million in 2014 to $2.06 billion in ... to 2020. India . ...
Breaking Biology News(10 mins):